Company intelligence / Profile preview

Socratech

Santiago de Compostela, Galicia, Spain

Ownership: Private
Development stage: Other

Overview

Socratech was a Spanish biotechnology company focused on the discovery and development of novel therapeutic agents for neurodegenerative disorders, primarily Alzheimer's disease. A spin-off from the University of Santiago de Compostela (USC), the company leveraged research from the BioFarma group to identify small molecules capable of modulating amyloid-beta aggregation. Its lead research efforts were centered on preventing the formation of toxic protein plaques in the brain to halt disease progression. While the company showed early promise in the Spanish biotech ecosystem, it is currently inactive or dissolved.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Socratech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Socratech.

Explore the full profile